24 results on '"Buttyan, R."'
Search Results
2. A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer progression
- Author
-
Stylianou, N, primary, Lehman, ML, additional, Wang, C, additional, Fard, AT, additional, Rockstroh, A, additional, Fazli, L, additional, Jovanovic, L, additional, Ward, M, additional, Sadowski, MC, additional, Kashyap, AS, additional, Buttyan, R, additional, Gleave, ME, additional, Westbrook, TF, additional, Williams, ED, additional, Gunter, JH, additional, Nelson, CC, additional, and Hollier, BG, additional
- Published
- 2019
- Full Text
- View/download PDF
3. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality
- Author
-
Tse, B W C, primary, Volpert, M, additional, Ratther, E, additional, Stylianou, N, additional, Nouri, M, additional, McGowan, K, additional, Lehman, M L, additional, McPherson, S J, additional, Roshan-Moniri, M, additional, Butler, M S, additional, Caradec, J, additional, Gregory-Evans, C Y, additional, McGovern, J, additional, Das, R, additional, Takhar, M, additional, Erho, N, additional, Alshalafa, M, additional, Davicioni, E, additional, Schaeffer, E M, additional, Jenkins, R B, additional, Ross, A E, additional, Karnes, R J, additional, Den, R B, additional, Fazli, L, additional, Gregory, P A, additional, Gleave, M E, additional, Williams, E D, additional, Rennie, P S, additional, Buttyan, R, additional, Gunter, J H, additional, Selth, L A, additional, Russell, P J, additional, Nelson, C C, additional, and Hollier, B G, additional
- Published
- 2017
- Full Text
- View/download PDF
4. Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells.
- Author
-
Yenki P, Bhasin S, Liu L, Nabavi N, Cheng CW, Tam KJ, Peacock JW, Adomat HH, Tombe T, Fazli L, Ivanova L, Dusek C, Khosravi S, Guns EST, Wang Y, Buttyan R, Gleave ME, and Ong CJ
- Subjects
- Male, Humans, Androgens metabolism, Androgen Antagonists, Receptors, Androgen metabolism, Cholesterol metabolism, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Prostatic Neoplasms, Castration-Resistant metabolism, Semaphorins genetics, Semaphorins metabolism
- Abstract
Intratumoral androgen biosynthesis contributes to castration-resistant prostate cancer progression in patients treated with androgen deprivation therapy. The molecular mechanisms by which castration-resistant prostate cancer acquires the capacity for androgen biosynthesis to bypass androgen deprivation therapy are not entirely known. Here, we show that semaphorin 3C, a secreted signaling protein that is highly expressed in castration-resistant prostate cancer, can promote steroidogenesis by altering the expression profile of key steroidogenic enzymes. Semaphorin 3C not only upregulates enzymes required for androgen synthesis from dehydroepiandrosterone or de novo from cholesterol but also simultaneously downregulates enzymes involved in the androgen inactivation pathway. These changes in gene expression correlate with increased production of androgens induced by semaphorin 3C in prostate cancer model cells. Moreover, semaphorin 3C upregulates androgen synthesis in LNCaP cell-derived xenograft tumors, likely contributing to the enhanced in vivo tumor growth rate post castration. Furthermore, semaphorin 3C activates sterol regulatory element-binding protein, a transcription factor that upregulates enzymes involved in the synthesis of cholesterol, a sole precursor for de novo steroidogenesis. The ability of semaphorin 3C to promote intratumoral androgen synthesis may be a key mechanism contributing to the reactivation of the androgen receptor pathway in castration-resistant prostate cancer, conferring continued growth under androgen deprivation therapy. These findings identify semaphorin 3C as a potential therapeutic target for suppressing intratumoral steroidogenesis.
- Published
- 2023
- Full Text
- View/download PDF
5. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
- Author
-
Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, Hanna MM, Mukherjee P, Sun B, Lee BR, Parker JB, Chakravarti D, Warfel NA, Zhou M, Bearss JJ, Gibb EA, Alshalalfa M, Karnes RJ, Small EJ, Aggarwal R, Feng F, Wang Y, Buttyan R, Zoubeidi A, Rubin M, Gleave M, Slack FJ, Davicioni E, Beltran H, Collins C, and Kraft AS
- Subjects
- Androgen Antagonists therapeutic use, Animals, Benzamides pharmacology, Benzamides therapeutic use, Biomarkers, Tumor metabolism, Carcinoma, Neuroendocrine diagnosis, Carcinoma, Neuroendocrine drug therapy, Cell Line, Tumor, Cell Lineage genetics, Cell Nucleus metabolism, Cell Proliferation genetics, Cohort Studies, DNA Methylation genetics, Disease Models, Animal, Drug Resistance, Neoplasm genetics, Epigenesis, Genetic drug effects, Genome, Human, Histones metabolism, Humans, Male, Neoplasm Grading, Neoplasm Invasiveness, Neoplastic Stem Cells metabolism, Nitriles pharmacology, Nitriles therapeutic use, Organoids metabolism, Organoids pathology, Phenylthiohydantoin pharmacology, Phenylthiohydantoin therapeutic use, Phylogeny, Polycomb Repressive Complex 2 metabolism, Promoter Regions, Genetic genetics, Prostatic Neoplasms diagnosis, Prostatic Neoplasms drug therapy, Protein Isoforms genetics, Protein Isoforms metabolism, RNA, Long Noncoding genetics, Receptors, Androgen metabolism, SOXB1 Transcription Factors metabolism, Transcription, Genetic drug effects, Carcinoma, Neuroendocrine genetics, Carcinoma, Neuroendocrine pathology, Cell Plasticity genetics, Gene Expression Regulation, Neoplastic, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology, RNA, Long Noncoding metabolism
- Abstract
Neuroendocrine (NE) prostate cancer (NEPC) is a lethal subtype of castration-resistant prostate cancer (PCa) arising either de novo or from transdifferentiated prostate adenocarcinoma following androgen deprivation therapy (ADT). Extensive computational analysis has identified a high degree of association between the long noncoding RNA (lncRNA) H19 and NEPC, with the longest isoform highly expressed in NEPC. H19 regulates PCa lineage plasticity by driving a bidirectional cell identity of NE phenotype (H19 overexpression) or luminal phenotype (H19 knockdown). It contributes to treatment resistance, with the knockdown of H19 re-sensitizing PCa to ADT. It is also essential for the proliferation and invasion of NEPC. H19 levels are negatively regulated by androgen signaling via androgen receptor (AR). When androgen is absent SOX2 levels increase, driving H19 transcription and facilitating transdifferentiation. H19 facilitates the PRC2 complex in regulating methylation changes at H3K27me3/H3K4me3 histone sites of AR-driven and NEPC-related genes. Additionally, this lncRNA induces alterations in genome-wide DNA methylation on CpG sites, further regulating genes associated with the NEPC phenotype. Our clinical data identify H19 as a candidate diagnostic marker and predictive marker of NEPC with elevated H19 levels associated with an increased probability of biochemical recurrence and metastatic disease in patients receiving ADT. Here we report H19 as an early upstream regulator of cell fate, plasticity, and treatment resistance in NEPC that can reverse/transform cells to a treatable form of PCa once therapeutically deactivated., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
6. Gli activation by the estrogen receptor in breast cancer cells: Regulation of cancer cell growth by Gli3.
- Author
-
Massah S, Foo J, Li N, Truong S, Nouri M, Xie L, Prins GS, and Buttyan R
- Subjects
- Cell Line, Tumor, Cell Nucleus drug effects, Cell Nucleus metabolism, Cell Proliferation drug effects, Estradiol pharmacology, Female, HEK293 Cells, Humans, Protein Stability drug effects, Breast Neoplasms metabolism, Breast Neoplasms pathology, Receptors, Estrogen metabolism, Zinc Finger Protein Gli3 metabolism
- Abstract
Background: Gli is an oncogenic transcription factor family thought to be involved in breast cancer (BrCa) cell growth. Gli activity is regulated by a post-translational proteolytic process that is suppressed by Hedgehog signaling. In prostate cancer cells, however, Gli activation is mediated by an interaction of active androgen receptor proteins with Gli3 that stabilizes Gli3 in its un-proteolyzed form. Here we show that the estrogen receptor (ER), ERα, also binds Gli3 and activates Gli in BrCa cells. Moreover, we show that ER + BrCa cells are dependent on Gli3 for cancer cell growth., Methods: Transfection with Gli-luciferase reporter was used to report Gli activity in 293FT or BrCa cells (MCF7, T47D, MDA-MB-453) with or without steroid ligands. Co-immunoprecipitation and proximity ligation were used to show association of Gli3 with ERα. Gli3 stability was determined by western blots of BrCa cell extracts. ERα knockdown or destabilization (by fulvestrant) was used to assess how loss of ERα affects estradiol-induced Gli reporter activity, formation of intranuclear ERα-Gli3 complexes and Gli3 stability. Expression of Gli1 and/or other endogenous Gli-target genes in BrCa cells were measured by qPCR in the presence or absence of estradiol. Gli3 knockdown was assessed for effects on BrCa cell growth using the Cyquant assay., Results: ERα co-transfection increased Gli reporter activity in 293FT cells that was further increased by estradiol. Gli3 co-precipitated in ERα immunoprecipitates. Acute (2 h) estradiol increased Gli reporter activity and the formation of intranuclear ERα-Gli3 complexes in ER + BrCa cells but more chronic estradiol (48 h) reduced ERα-Gli complexes commensurate with reduced ERα levels. Gli3 stability and endogenous activity was only increased by more chronic estradiol treatment. Fulvestrant or ERα knockdown suppressed E2-induction of Gli activity, intranuclear ERα-Gli3 complexes and stabilization of Gli3. Gli3 knockdown significantly reduced the growth of BrCa cells., Conclusions: ERα interacts with Gli3 in BrCa cells and estradiol treatment leads to Gli3 stabilization and increased expression of Gli-target genes. Furthermore, we found tthat Gli3 is necessary for BrCa cell growth. These results support the idea that the ERα-Gli interaction and Gli3 may be novel targets for effective control of BrCa growth., (Copyright © 2020. Published by Elsevier B.V.)
- Published
- 2021
- Full Text
- View/download PDF
7. Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer.
- Author
-
Nouri M, Massah S, Caradec J, Lubik AA, Li N, Truong S, Lee AR, Fazli L, Ramnarine VR, Lovnicki JM, Moore J, Wang M, Foo J, Gleave ME, Hollier BG, Nelson C, Collins C, Dong X, and Buttyan R
- Subjects
- Animals, Cell Line, Tumor, Humans, Male, Mice, NF-kappa B metabolism, Neuroendocrine Cells metabolism, Prostatic Neoplasms, Castration-Resistant drug therapy, Prostatic Neoplasms, Castration-Resistant genetics, Prostatic Neoplasms, Castration-Resistant metabolism, Receptors, Androgen genetics, Retinoblastoma Protein genetics, Retinoblastoma Protein metabolism, SOX9 Transcription Factor genetics, SOXB1 Transcription Factors genetics, SOXB1 Transcription Factors metabolism, Signal Transduction, Stem Cells metabolism, Tumor Suppressor Protein p53 genetics, Tumor Suppressor Protein p53 metabolism, Xenograft Model Antitumor Assays, Androgen Receptor Antagonists pharmacology, Drug Resistance, Neoplasm, Neuroendocrine Cells pathology, Prostatic Neoplasms, Castration-Resistant pathology, Receptors, Androgen metabolism, SOX9 Transcription Factor metabolism, Stem Cells pathology
- Abstract
Purpose: Patients with metastatic prostate cancer are increasingly presenting with treatment-resistant, androgen receptor-negative/low (AR
-/Low ) tumors, with or without neuroendocrine characteristics, in processes attributed to tumor cell plasticity. This plasticity has been modeled by Rb1/p53 knockdown/knockout and is accompanied by overexpression of the pluripotency factor, Sox2. Here, we explore the role of the developmental transcription factor Sox9 in the process of prostate cancer therapy response and tumor progression., Experimental Design: Unique prostate cancer cell models that capture AR-/Low stem cell-like intermediates were analyzed for features of plasticity and the functional role of Sox9. Human prostate cancer xenografts and tissue microarrays were evaluated for temporal alterations in Sox9 expression. The role of NF-κB pathway activity in Sox9 overexpression was explored., Results: Prostate cancer stem cell-like intermediates have reduced Rb1 and p53 protein expression and overexpress Sox2 as well as Sox9. Sox9 was required for spheroid growth, and overexpression increased invasiveness and neural features of prostate cancer cells. Sox9 was transiently upregulated in castration-induced progression of prostate cancer xenografts and was specifically overexpressed in neoadjuvant hormone therapy (NHT)-treated patient tumors. High Sox9 expression in NHT-treated patients predicts biochemical recurrence. Finally, we link Sox9 induction to NF-κB dimer activation in prostate cancer cells., Conclusions: Developmentally reprogrammed prostate cancer cell models recapitulate features of clinically advanced prostate tumors, including downregulated Rb1/p53 and overexpression of Sox2 with Sox9. Sox9 is a marker of a transitional state that identifies prostate cancer cells under the stress of therapeutic assault and facilitates progression to therapy resistance. Its expression may index the relative activity of the NF-κB pathway., (©2020 American Association for Cancer Research.)- Published
- 2020
- Full Text
- View/download PDF
8. Erythropoietin promotes functional recovery via anti-apoptotic mechanisms in mouse unilateral ureteral obstruction.
- Author
-
Park E, Cox M, Scotland K, Buttyan R, and Lange D
- Subjects
- Animals, Apoptosis drug effects, Female, Mice, Mice, Inbred C57BL, Recovery of Function, Epoetin Alfa administration & dosage, Epoetin Alfa pharmacology, Kidney drug effects, Kidney injuries, Protective Agents administration & dosage, Protective Agents pharmacology, Ureter drug effects, Ureter injuries, Ureteral Obstruction drug therapy
- Abstract
The purpose of the work was to investigate mechanisms of erythropoietin-induced protection and accelerated recovery of kidneys and ureters from obstructive injury. Unilateral ureteral obstruction was established for 24, 48, and 72 h in C57BL/6 mice using a non-traumatic micro-clip followed by the microscopic quantification of ureteral peristalsis pre- and post-obstruction. Expression of erythropoietin, erythropoietin receptor, β-common receptor, and downstream apoptosis-related markers was assessed by RT-PCR and immunohistochemistry in ureters and kidneys and compared to the respective organs on the contralateral side within each animal. Expression of genes in kidneys and ureters from mice treated with 20 IU of erythropoietin daily for 72 h prior to obstruction was compared to that of untreated mice following obstruction. Apoptosis in ureteral tissues after 72-h obstruction was assessed via TUNEL assay. Ureteral obstruction increased apoptosis in affected ureters, with peristaltic function halted following all periods of obstruction. Erythropoietin treatment suppressed apoptosis in obstructed tissues and increased the percentage of mice retaining ureteral function immediately following obstruction reversal. Erythropoietin, erythropoietin receptor, Bcl-2, and Bcl-xl mRNA expression were down-regulated, while phospho-Nf-ĸb p65 was up-regulated in ureteral epithelia following obstruction. Erythropoietin treatment induced anti-apoptotic signaling via down-regulated Bax mRNA expression and abrogated phospho-Nf-ĸb p65. Erythropoietin-induced protection of ureteral function and accelerated recovery post-obstruction removal is mediated via anti-apoptotic mechanisms. Ureteral function is disrupted even following obstruction removal, negatively affecting renal function due to delayed recovery. Thus, our results represent a potential target for the development of safe therapeutic agents aimed at improving functional recovery from obstructive injury.
- Published
- 2020
- Full Text
- View/download PDF
9. Inhibition of GLI2 with antisense-oligonucleotides: A potential therapy for the treatment of bladder cancer.
- Author
-
Raven PA, Lysakowski S, Tan Z, D'Costa NM, Moskalev I, Frees S, Struss W, Matsui Y, Narita S, Buttyan R, Chavez-Munoz C, and So AI
- Subjects
- Antineoplastic Agents pharmacology, Cell Cycle, Cell Line, Tumor, Cell Survival, Humans, Nuclear Proteins genetics, Nuclear Proteins metabolism, Zinc Finger Protein Gli2 genetics, Zinc Finger Protein Gli2 metabolism, Gene Expression Regulation, Neoplastic drug effects, Nuclear Proteins agonists, Nuclear Proteins antagonists & inhibitors, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms metabolism, Zinc Finger Protein Gli2 agonists, Zinc Finger Protein Gli2 antagonists & inhibitors
- Abstract
The sonic hedgehog (SHH) signaling pathway plays an integral role in the maintenance and progression of bladder cancer (BCa) and SHH inhibition may be an efficacious strategy for BCa treatment. We assessed an in-house human BCa tissue microarray and found that the SHH transcription factors, GLI1 and GLI2, were increased in disease progression. A panel of BCa cell lines show that two invasive lines, UM-UC-3 and 253J-BV, both express these transcription factors but UM-UC-3 produces more SHH ligand and is less responsive in viability to pathway stimulation by recombinant human SHH or smoothened agonist, and less responsive to inhibitors including the smoothened inhibitors cyclopamine and SANT-1. In contrast, 253J-BV was highly responsive to these manipulations. We utilized a GLI1 and GLI2 antisense oligonucleotide (ASO) to bypass pathway mechanics and target the transcription factors directly. UM-UC-3 decreased in viability due to both ASOs but 253J-BV was only affected by GLI2 ASO. We utilized the murine intravesical orthotopic human BCa (mio-hBC) model for the establishment of noninvasive BCa and treated tumors with GLI2 ASO. Tumor size, growth rate, and GLI2 messenger RNA and protein expression were decreased. These results suggest that GLI2 ASO may be a promising new targeted therapy for BCa., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
10. The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management.
- Author
-
Ramnarine VR, Kobelev M, Gibb EA, Nouri M, Lin D, Wang Y, Buttyan R, Davicioni E, Zoubeidi A, and Collins CC
- Subjects
- Biomarkers, Tumor analysis, Biomarkers, Tumor genetics, Humans, Male, Pharmacogenetics, Procedures and Techniques Utilization, Prognosis, Drug Discovery, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology, Prostatic Neoplasms therapy, RNA, Long Noncoding analysis, RNA, Long Noncoding genetics
- Abstract
Context: It is increasingly evident that non-protein-coding regions of the genome can give rise to transcripts that form functional layers of the cancer genome. One of most abundant classes in these regions is long noncoding RNAs (lncRNAs). They have gained increasing attention in prostate cancer (PCa) and paved the way for a greater understanding of these cryptic regulators in cancer., Objective: To review current research exploring the functional biology of lncRNAs in PCa over the past three decades., Evidence Acquisition: A systematic review was performed using PubMed to search for reports with terms "long noncoding RNA", "prostate", and "cancer" over the past 30 yr (1988-2018)., Evidence Synthesis: We comprehensively surveyed the literature collected and summarise experiments leading to the characterisation of lncRNAs in PCa. A historical timeline of lncRNA identification is described, where each lncRNA is categorised mechanistically and within the primary areas of carcinogenesis: tumour risk and initiation, tumour promotion, tumour suppression, and tumour treatment resistance. We describe select lncRNAs that exemplify these areas. We also review whether these lncRNAs have a clinical utility in PCa diagnosis, prognosis, and prediction, and as therapeutic targets., Conclusions: The biology of lncRNA is multifaceted, demonstrating a complex array of molecular and cellular functions. These studies reveal that lncRNAs are involved in every stage of PCa. Their clinical utility for diagnosis, prognosis, and prediction of PCa is well supported, but further evaluation for their therapeutic candidacy is needed. We provide a detailed resource and view inside the lncRNA landscape for other cancer biologists, oncologists, and clinicians., Patient Summary: In this study, we review current knowledge of the non-protein-coding genome in prostate cancer (PCa). We conclude that many of these regions are functional and a source of accurate biomarkers in PCa. With a strong research foundation, they hold promise as future therapeutic targets, yet clinical trials are necessary to determine their intrinsic value to PCa disease management., (Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
11. Correction: A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome.
- Author
-
Stylianou N, Lehman ML, Wang C, Fard AT, Rockstroh A, Fazli L, Jovanovic L, Ward M, Sadowski MC, Kashyap AS, Buttyan R, Gleave ME, Westbrook TF, Williams ED, Gunter JH, Nelson CC, and Hollier BG
- Abstract
Following the publication of the above article, the authors noted an error in Figure 4, panel B. The colours of the localized and mCRPC samples were accidentally switched. The authors have corrected the colour scheme and added a key to the figure. They have also updated the colour scheme of panel C, both bars are now red instead of one red and one blue. The authors wish to apologize for any inconvenience caused.
- Published
- 2019
- Full Text
- View/download PDF
12. A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome.
- Author
-
Stylianou N, Lehman ML, Wang C, Fard AT, Rockstroh A, Fazli L, Jovanovic L, Ward M, Sadowski MC, Kashyap AS, Buttyan R, Gleave ME, Westbrook TF, Williams ED, Gunter JH, Nelson CC, and Hollier BG
- Subjects
- Cell Line, Tumor, Disease-Free Survival, Humans, Male, Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant classification, Prostatic Neoplasms, Castration-Resistant pathology, Survival Rate, Epithelial-Mesenchymal Transition, Prostatic Neoplasms, Castration-Resistant metabolism, Prostatic Neoplasms, Castration-Resistant mortality
- Abstract
The propensity of cancer cells to transition between epithelial and mesenchymal phenotypic states via the epithelial-mesenchymal transition (EMT) program can regulate metastatic processes, cancer progression, and treatment resistance. Transcriptional investigations using reversible models of EMT, revealed the mesenchymal-to-epithelial reverting transition (MErT) to be enriched in clinical samples of metastatic castrate resistant prostate cancer (mCRPC). From this enrichment, a metastasis-derived gene signature was identified that predicted more rapid cancer relapse and reduced survival across multiple human carcinoma types. Additionally, the transcriptional profile of MErT is not a simple mirror image of EMT as tumour cells retain a transcriptional "memory" following a reversible EMT. This memory was also enriched in mCRPC samples. Cumulatively, our studies reveal the transcriptional profile of epithelial-mesenchymal plasticity and highlight the unique transcriptional properties of MErT. Furthermore, our findings provide evidence to support the association of epithelial plasticity with poor clinical outcomes in multiple human carcinoma types.
- Published
- 2019
- Full Text
- View/download PDF
13. Correction: Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells.
- Author
-
Chen R, Li Y, Buttyan R, and Dong X
- Abstract
[This corrects the article DOI: 10.18632/oncotarget.19386.].
- Published
- 2018
- Full Text
- View/download PDF
14. Hedgehog in prostate cancer explained.
- Author
-
Buttyan R, Li N, and Massah S
- Abstract
Competing Interests: CONFLICTS OF INTEREST The authors declare no potential conflicts of interest.
- Published
- 2018
- Full Text
- View/download PDF
15. Non-canonical activation of hedgehog in prostate cancer cells mediated by the interaction of transcriptionally active androgen receptor proteins with Gli3.
- Author
-
Li N, Truong S, Nouri M, Moore J, Al Nakouzi N, Lubik AA, and Buttyan R
- Subjects
- Cell Line, Tumor, Gene Expression Regulation, Neoplastic, HEK293 Cells, Humans, Male, Promoter Regions, Genetic, Prostatic Neoplasms metabolism, Prostatic Neoplasms pathology, Protein Binding, Signal Transduction physiology, Transcription Factors metabolism, Transcriptional Activation, Hedgehog Proteins genetics, Nerve Tissue Proteins metabolism, Prostatic Neoplasms genetics, Receptors, Androgen metabolism, Zinc Finger Protein Gli3 metabolism
- Abstract
Hedgehog (Hh) is an oncogenic signaling pathway that regulates the activity of Gli transcription factors. Canonical Hh is a Smoothened- (Smo-) driven process that alters the post-translational processing of Gli2/Gli3 proteins. Though evidence supports a role for Gli action in prostate cancer (PCa) cell growth and progression, there is little indication that Smo is involved. Here we describe a non-canonical means for activation of Gli transcription in PCa cells mediated by the binding of transcriptionally-active androgen receptors (ARs) to Gli3. Androgens stimulated reporter expression from a Gli-dependent promoter in a variety of AR + PCa cells and this activity was suppressed by an anti-androgen, Enz, or by AR knockdown. Androgens also upregulated expression of endogenous Gli-dependent genes. This activity was associated with increased intranuclear binding of Gli3 to AR that was antagonized by Enz. Fine mapping of the AR binding domain on Gli2 showed that AR recognizes the Gli protein processing domain (PPD) in the C-terminus. Mutations in the arginine-/serine repeat elements of the Gli2 PPD involved in phosphorylation and ubiquitinylation blocked the binding to AR. β-TrCP, a ubiquitin ligase that recognizes the Gli PPD, competed with AR for binding to this site. AR binding to Gli3 suppressed its proteolytic processing to the Gli3 repressor form (Gli3R) whereas AR knockdown increased Gli3R. Both full-length and truncated ARs were able to activate Gli transcription. Finally, we found that an ARbinding decoy polypeptide derived from the Gli2 C-terminus can compete with Gli3 for binding to AR. Exogenous overexpression of this decoy suppressed Gli transcriptional activity in PCa cells. Collectively, this work identifies a novel pathway for non-canonical activation of Hh signaling in PCa cells and identifies a means for interference that may have clinical relevance for PCa patients.
- Published
- 2018
- Full Text
- View/download PDF
16. Semaphorin 3 C drives epithelial-to-mesenchymal transition, invasiveness, and stem-like characteristics in prostate cells.
- Author
-
Tam KJ, Hui DHF, Lee WW, Dong M, Tombe T, Jiao IZF, Khosravi S, Takeuchi A, Peacock JW, Ivanova L, Moskalev I, Gleave ME, Buttyan R, Cox ME, and Ong CJ
- Subjects
- Animals, Biomarkers, Cell Line, Tumor, Cell Movement, Cell Proliferation, Disease Models, Animal, Gene Expression, Heterografts, Humans, Immunophenotyping, Male, Mice, Neoplasm Invasiveness, Prostatic Neoplasms pathology, Epithelial-Mesenchymal Transition genetics, Neoplastic Stem Cells metabolism, Prostatic Neoplasms genetics, Prostatic Neoplasms metabolism, Semaphorins genetics
- Abstract
Prostate cancer (PCa) is among the most commonly-occurring cancers worldwide and a leader in cancer-related deaths. Local non-invasive PCa is highly treatable but limited treatment options exist for those with locally-advanced and metastatic forms of the disease underscoring the need to identify mechanisms mediating PCa progression. The semaphorins are a large grouping of membrane-associated or secreted signalling proteins whose normal roles reside in embryogenesis and neuronal development. In this context, semaphorins help establish chemotactic gradients and direct cell movement. Various semaphorin family members have been found to be up- and down-regulated in a number of cancers. One family member, Semaphorin 3 C (SEMA3C), has been implicated in prostate, breast, ovarian, gastric, lung, and pancreatic cancer as well as glioblastoma. Given SEMA3C's roles in development and its augmented expression in PCa, we hypothesized that SEMA3C promotes epithelial-to-mesenchymal transition (EMT) and stem-like phenotypes in prostate cells. In the present study we show that ectopic expression of SEMA3C in RWPE-1 promotes the upregulation of EMT and stem markers, heightened sphere-formation, and cell plasticity. In addition, we show that SEMA3C promotes migration and invasion in vitro and cell dissemination in vivo.
- Published
- 2017
- Full Text
- View/download PDF
17. Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells.
- Author
-
Chen R, Li Y, Buttyan R, and Dong X
- Abstract
Treatment-induced neuroendocrine prostate cancer (t-NEPC) is an aggressive subtype of prostate cancer (PCa) that arises as a consequence of rigorous androgen receptor (AR) pathway inhibition (ARPI) therapies. While the PI3K/AKT pathway has been investigated as a co-therapeutic target with ARPI for advanced PCa, whether this strategy can prevent tumor progression to t-NEPC remains unknown. Here, we report that PI3K/AKT inhibition alone reduces RE-1 silencing transcription factor (REST) protein expression and induces multiple NE markers in PCa cells. The loss of REST by PI3K/AKT inhibition is through protein degradation mediated by the E3-ubiquitin ligase β-TRCP and REST phosphorylations at the S1024, S1027, and S1030 sites. Since AR inhibition can also deplete REST, the combinational inhibition of PI3K/AKT and AR further aggravated REST protein reduction. We profiled the transcriptomes of AKT and AR inhibitions in the LNCaP cells. The Gene Set Enrichment Analysis (GSEA) showed that these transcriptomes are highly correlated with the REST-regulated gene signature. Co-targeting AKT and AR resulted in a higher correlation comparing to those of single treatment. Comparing these transcriptomes to the t-NEPC gene signature in patients by GSEA, we observed that adding AKT inhibition to AR blockade enhanced the expression of neurogenesis-related genes and resulted in a stronger and broader upregulation of REST-regulated genes specific to t-NEPC. These results indicate that AKT pathway inhibition can induce neuroendocrine differentiation of PCa cells via REST protein degradation. It delineates a potential risk for the AR and PI3K/AKT co-targeting strategy as it may further facilitate t-NEPC development., Competing Interests: CONFLICTS OF INTEREST The authors declare no conflict of interest.
- Published
- 2017
- Full Text
- View/download PDF
18. A Role for the Hedgehog Effector Gli1 in Mediating Stent-induced Ureteral Smooth Muscle Dysfunction and Aperistalsis.
- Author
-
Janssen C, Buttyan R, Seow CY, Jäger W, Solomon D, Fazli L, Chew BH, and Lange D
- Subjects
- Animals, Gene Expression Regulation, Inflammation, Peristalsis, Signal Transduction, Stents, Swine, Time Factors, Ureteral Obstruction pathology, Muscle, Smooth metabolism, Ureter metabolism, Zinc Finger Protein GLI1 metabolism
- Abstract
Objective: To better understand the effects of double J stenting on ureteral physiology and function., Materials and Methods: In total, 24 pigs were stented cystoscopically unilaterally for 48 hours, 1, 2, 4, and 7 weeks. Controls consisted of un-stented animals (n = 4) or the contralateral un-stented ureter in pigs. Ureters were harvested and tested in tissue baths to evaluate their contractility. Ureteral inflammation and expression of Sonic Hedgehog (Shh) and the transcriptional activator Gli1 (the downstream target of active Hedgehog signaling) were assessed histologically and by immunohistochemistry, respectively., Results: Indwelling ureteral stents were found to abolish normal ureteral function in all animals. Specifically, ureteral smooth muscle (SM) activity was significantly diminished within 48 hours after stenting and persisted at the 1-week time point. Furthermore, ureteral SM dysfunction was associated with increasing ureteral dilation due to the indwelling stent. Simultaneously, we observed a loss of Gli1 expression in SM cells, with a concomitant increase in ureteral inflammation. Expression of Shh was restricted to the urothelium and was not different between controls, stented, and contralateral ureters., Conclusion: Stent-induced aperistalsis was associated with diminished SM contractility, increased tissue inflammation, and reduced Gli1 expression in ureteral SM cells, independent of Shh expression. The present study is the first to show that indwelling stents negatively affect ureteral SM activity and identify a role for specific molecular mechanisms involved., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
19. Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.
- Author
-
Nouri M, Caradec J, Lubik AA, Li N, Hollier BG, Takhar M, Altimirano-Dimas M, Chen M, Roshan-Moniri M, Butler M, Lehman M, Bishop J, Truong S, Huang SC, Cochrane D, Cox M, Collins C, Gleave M, Erho N, Alshalafa M, Davicioni E, Nelson C, Gregory-Evans S, Karnes RJ, Jenkins RB, Klein EA, and Buttyan R
- Subjects
- Animals, Blotting, Western, Disease Progression, Flow Cytometry, Fluorescent Antibody Technique, Heterografts, Humans, Male, Mice, Oligonucleotide Array Sequence Analysis, Real-Time Polymerase Chain Reaction, Zebrafish, Cell Transdifferentiation physiology, Cellular Reprogramming physiology, Drug Resistance, Neoplasm physiology, Neoplastic Stem Cells pathology, Prostatic Neoplasms pathology
- Abstract
Treatment-induced neuroendocrine transdifferentiation (NEtD) complicates therapies for metastatic prostate cancer (PCa). Based on evidence that PCa cells can transdifferentiate to other neuroectodermally-derived cell lineages in vitro, we proposed that NEtD requires first an intermediary reprogramming to metastable cancer stem-like cells (CSCs) of a neural class and we demonstrate that several different AR+/PSA+ PCa cell lines were efficiently reprogrammed to, maintained and propagated as CSCs by growth in androgen-free neural/neural crest (N/NC) stem medium. Such reprogrammed cells lost features of prostate differentiation; gained features of N/NC stem cells and tumor-initiating potential; were resistant to androgen signaling inhibition; and acquired an invasive phenotype in vitro and in vivo. When placed back into serum-containing mediums, reprogrammed cells could be re-differentiated to N-/NC-derived cell lineages or return back to an AR+ prostate-like state. Once returned, the AR+ cells were resistant to androgen signaling inhibition. Acute androgen deprivation or anti-androgen treatment in serum-containing medium led to the transient appearance of a sub-population of cells with similar characteristics. Finally, a 132 gene signature derived from reprogrammed PCa cell lines distinguished tumors from PCa patients with adverse outcomes. This model may explain neural manifestations of PCa associated with lethal disease. The metastable nature of the reprogrammed stem-like PCa cells suggests that cycles of PCa cell reprogramming followed by re-differentiation may support disease progression and therapeutic resistance. The ability of a gene signature from reprogrammed PCa cells to identify tumors from patients with metastasis or PCa-specific mortality implies that developmental reprogramming is linked to aggressive tumor behaviors.
- Published
- 2017
- Full Text
- View/download PDF
20. Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.
- Author
-
Lubik AA, Nouri M, Truong S, Ghaffari M, Adomat HH, Corey E, Cox ME, Li N, Guns ES, Yenki P, Pham S, and Buttyan R
- Subjects
- Androgens metabolism, Animals, Bone Marrow metabolism, Castration methods, Cell Line, Tumor, Humans, Male, Mice, Mice, Nude, Receptors, Androgen metabolism, Signal Transduction physiology, Stromal Cells metabolism, Testosterone metabolism, Hedgehog Proteins metabolism, Paracrine Communication physiology, Prostatic Neoplasms, Castration-Resistant metabolism, Prostatic Neoplasms, Castration-Resistant pathology, Tumor Microenvironment physiology
- Abstract
Despite the substantial benefit of androgen deprivation therapy (ADT) for metastatic prostate cancer, patients often progress to castration-resistant disease (CRPC) that is more difficult to treat. CRPC is associated with renewed androgen receptor activity in tumor cells and restoration of tumor androgen levels through acquired intratumoral steroidogenesis (AIS). Although prostate cancer (PCa) cells have been shown to have steroidogenic capability in vitro, we previously found that benign prostate stromal cells (PrSCs) can also synthesize testosterone (T) from an adrenal precursor, DHEA, when stimulated with a hedgehog (Hh) pathway agonist, SAG. Here, we show exposure of PrSCs to a different Smoothened (Smo) agonist, Ag1.5, or to conditioned medium from sonic hedgehog overexpressing LNCaP cells induces steroidogenic enzyme expression in PrSCs and significantly increases production of T and its precursor steroids in a Smo-dependent manner from 22-OH-cholesterol substrate. Hh agonist-/ligand-treated PrSCs produced androgens at a rate similar to or greater than that of PCa cell lines. Likewise, primary bone marrow stromal cells became more steroidogenic and produced T under the influence of Smo agonist. Treatment of mice bearing LNCaP xenografts with a Smo antagonist, TAK-441, delayed the onset of CRPC after castration and substantially reduced androgen levels in residual tumors. These outcomes support the idea that stromal cells in ADT-treated primary or metastatic prostate tumors can contribute to AIS as a consequence of a paracrine Hh signaling microenvironment. As such, Smo antagonists may be useful for targeting prostate tumor stromal cell-derived AIS and delaying the onset of CRPC after ADT., (© 2016 UICC.)
- Published
- 2017
- Full Text
- View/download PDF
21. Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy.
- Author
-
Hayashi T, Gust KM, Wyatt AW, Goriki A, Jäger W, Awrey S, Li N, Oo HZ, Altamirano-Dimas M, Buttyan R, Fazli L, Matsubara A, and Black PC
- Subjects
- Animals, Cell Line, Tumor, Cell Proliferation genetics, Enzyme Activation genetics, Gene Dosage genetics, Humans, Lymphatic Metastasis genetics, Mice, Neoplasm Invasiveness genetics, RNA Interference, RNA, Small Interfering genetics, Receptor, Notch1 biosynthesis, Receptor, Notch2 antagonists & inhibitors, Receptor, Notch3 biosynthesis, Signal Transduction genetics, Xenograft Model Antitumor Assays, Epithelial-Mesenchymal Transition genetics, Receptor, Notch2 genetics, Receptor, Notch2 metabolism, Urinary Bladder Neoplasms pathology
- Abstract
Purpose: Recent molecular analyses of bladder cancer open the door to significant advances in targeted therapies. NOTCH has been identified as a tumor suppressor in bladder cancer, but prior reports have focused on NOTCH1 Here we hypothesized that NOTCH2 is an oncogene suitable for therapeutic targeting in bladder cancer., Experimental Design: We studied genomic aberrations of NOTCH, compared survival and tumor progression according to NOTCH2 expression levels, and studied NOTCH2 function in vitro and vivo, Results: We report a high rate of NOTCH2 copy number gain in bladder cancer. High NOTCH2 expression was identified especially in the basal subtype and in mesenchymal tumors. NOTCH2 activation correlated with adverse disease parameters and worse prognosis by immunohistochemistry. Forced overexpression of the intracellular domain of NOTCH2 (N2ICD) induced cell growth and invasion by cell-cycle progression, maintenance of stemness and epithelial-to-mesenchymal transition (EMT). These effects were abrogated by silencing of CSL, indicating that the effects were mediated through the canonical NOTCH signaling pathway. In an orthotopic xenograft model, forced overexpression of N2ICD increased growth, invasion, and metastasis. To explore the potential for therapeutic targeting of NOTCH2, we first silenced the receptor with shRNA and subsequently treated with a specific inhibitory antibody. Both interventions decreased cell growth, invasion, and metastasis in vitro and in the orthotopic xenograft model., Conclusions: We have demonstrated that NOTCH2 acts as an oncogene that promotes bladder cancer growth and metastasis through EMT, cell-cycle progression, and maintenance of stemness. Inhibition of NOTCH2 is a rational novel treatment strategy for invasive bladder cancer. Clin Cancer Res; 22(12); 2981-92. ©2016 AACR., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
22. FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer.
- Author
-
Han B, Qu Y, Jin Y, Yu Y, Deng N, Wawrowsky K, Zhang X, Li N, Bose S, Wang Q, Sakkiah S, Abrol R, Jensen TW, Berman BP, Tanaka H, Johnson J, Gao B, Hao J, Liu Z, Buttyan R, Ray PS, Hung MC, Giuliano AE, and Cui X
- Subjects
- Binding Sites, Breast Neoplasms genetics, Breast Neoplasms pathology, Cell Line, Tumor, Female, Forkhead Transcription Factors chemistry, HEK293 Cells, Humans, Kruppel-Like Transcription Factors chemistry, Nuclear Proteins chemistry, Protein Binding, Signal Transduction, Smoothened Receptor, Zinc Finger Protein Gli2, Breast Neoplasms metabolism, Forkhead Transcription Factors metabolism, Gene Expression Regulation, Neoplastic, Kruppel-Like Transcription Factors metabolism, Nuclear Proteins metabolism, Receptors, G-Protein-Coupled metabolism
- Abstract
The mesoderm- and epithelial-mesenchymal transition-associated transcription factor FOXC1 is specifically overexpressed in basal-like breast cancer (BLBC), but its biochemical function is not understood. Here, we demonstrate that FOXC1 controls cancer stem cell (CSC) properties enriched in BLBC cells via activation of Smoothened (SMO)-independent Hedgehog (Hh) signaling. This non-canonical activation of Hh is specifically mediated by Gli2. Furthermore, we show that the N-terminal domain of FOXC1 (aa 1-68) binds directly to an internal region (aa 898-1168) of Gli2, enhancing the DNA-binding and transcription-activating capacity of Gli2. FOXC1 expression correlates with that of Gli2 and its targets in human breast cancers. Moreover, FOXC1 overexpression reduces sensitivity to anti-Hedgehog (Hh) inhibitors in BLBC cells and xenograft tumors. Together, these findings reveal FOXC1-mediated non-canonical Hh signaling that determines the BLBC stem-like phenotype and anti-Hh sensitivity, supporting inhibition of FOXC1 pathways as potential approaches for improving BLBC treatment., (Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
23. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells.
- Author
-
Levina E, Ji H, Chen M, Baig M, Oliver D, Ohouo P, Lim CU, Schools G, Carmack S, Ding Y, Broude EV, Roninson IB, Buttyan R, and Shtutman M
- Subjects
- Cell Line, Tumor, Cell Proliferation genetics, Disease Progression, Gene Expression, Humans, Male, Promoter Regions, Genetic, Prostatic Neoplasms metabolism, Prostatic Neoplasms pathology, Prostatic Neoplasms, Castration-Resistant genetics, Prostatic Neoplasms, Castration-Resistant metabolism, Prostatic Neoplasms, Castration-Resistant pathology, RNA, Small Interfering administration & dosage, RNA, Small Interfering genetics, Receptors, Androgen metabolism, Signal Transduction genetics, Androgens deficiency, Prostatic Neoplasms genetics, Receptors, Androgen genetics
- Abstract
Prostate cancer progression to castration refractory disease is associated with anomalous transcriptional activity of the androgen receptor (AR) in an androgen-depleted milieu. To identify novel gene products whose downregulation transactivates AR in prostate cancer cells, we performed a screen of enzymatically-generated shRNA lenti-libraries selecting for transduced LNCaP cells with elevated expression of a fluorescent reporter gene under the control of an AR-responsive promoter. The shRNAs present in selected populations were analyzed using high-throughput sequencing to identify target genes. Highly enriched gene targets were then validated with siRNAs against selected genes, testing first for increased expression of luciferase from an AR-responsive promoter and then for altered expression of endogenous androgen-regulated genes in LNCaP cells. We identified 20 human genes whose silencing affected the expression of exogenous and endogenous androgen-responsive genes in prostate cancer cells grown in androgen-depleted medium. Knockdown of four of these genes upregulated the expression of endogenous AR targets and siRNAs targeting two of these genes (IGSF8 and RTN1) enabled androgen-independent proliferation of androgen-dependent cells. The effects of IGSF8 appear to be mediated through its interaction with a tetraspanin protein, CD9, previously implicated in prostate cancer progression. Remarkably, homozygous deletions of IGSF8 are found almost exclusively in prostate cancers but not in other cancer types. Our study shows that androgen independence can be achieved through the inhibition of specific genes and reveals a novel set of genes that regulate AR signaling in prostate cancers.
- Published
- 2015
- Full Text
- View/download PDF
24. Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors.
- Author
-
Li N, Chen M, Truong S, Yan C, and Buttyan R
- Subjects
- Cell Line, Tumor, DNA, Neoplasm genetics, Gene Expression Regulation, Neoplastic, HEK293 Cells, Humans, Immunoprecipitation, Kruppel-Like Transcription Factors genetics, Male, Nuclear Proteins genetics, Prostatic Neoplasms genetics, Prostatic Neoplasms, Castration-Resistant genetics, Prostatic Neoplasms, Castration-Resistant metabolism, Protein Structure, Tertiary, Receptors, Androgen genetics, Response Elements, Transcription Factors genetics, Transcription Factors metabolism, Transcriptional Activation, Transfection, Zinc Finger Protein GLI1, Zinc Finger Protein Gli2, Kruppel-Like Transcription Factors metabolism, Nuclear Proteins metabolism, Prostatic Neoplasms metabolism, Receptors, Androgen metabolism
- Abstract
Background: Gli2, a transcription factor in the Hedgehog pathway, is overexpressed in castrate-resistant prostate cancer (PCa). Previously we showed that Gli2 overexpression increased transcriptional activity of androgen receptor (AR) and conferred androgen growth-independence to normally growth-dependent PCa cells. Here we localized the regions of AR-Gli2 protein interaction and determined the domains within Gli2 needed for AR co-activation., Methods: Co-immunoprecipitation and GST-pulldown assays were used to define AR-Gli binding domains. Co-activation assays using androgen-responsive promoter reporters were used to define Gli2 regions needed for AR co-activation. Chromatin immunoprecipitation (ChIP) assays were used to confirm nuclear interactions of Gli2 with AR in PCa cells., Results: The Gli2 C-terminal domain (CTD) is sufficient for AR co-activation. Two elements within the CTD were required: (1) an AR binding domain within aa628-897; and (2) at least part of the Gli2 transactivation domain within aa1252-1586. In turn, Gli2 binds the tau5/AF5 ligand-independent activation domain in the AR N-terminus. Mutations in the WxxLF motif in tau5/AF5 greatly diminished binding to Gli2-CTD. Gli2 interaction with AR tau5/AF5 was further substantiated by the ability of Gli2/Gli2-CTD to co-activate truncated AR splice variants (AR-V7/ARV567es). ChIP assays confirmed that Gli2 associates with chromatin at androgen response elements found near androgen-responsive genes in LNCaP cells. These assays also showed that AR associates with chromatin containing a Gli-response element near a Gli-responsive gene., Conclusion: Our findings indicate that Gli2 overexpression in PCa cells might support development of castration resistant PCa through AR co-activation and suggests that AR might modulate transcription from Gli2., (© 2014 Wiley Periodicals, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.